Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1750

1.

Insulin lispro protamine suspension in intensive insulin treatment: an Italian observational study.

Citro G, Lorusso B, Rossi A, Romaniello M, Gentilella R, Cremasco F.

Curr Med Res Opin. 2009 Sep;25(9):2259-65. doi: 10.1185/03007990903166474.

PMID:
19630489
2.

Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.

Wenying Y, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Ligthelm R, Valensi P; IMPROVE Study Group Expert Panel.

Curr Med Res Opin. 2009 Nov;25(11):2643-54. doi: 10.1185/03007990903276745.

PMID:
19751116
3.

Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.

Blonde L, Merilainen M, Karwe V, Raskin P; TITRATE Study Group.

Diabetes Obes Metab. 2009 Jun;11(6):623-31. doi: 10.1111/j.1463-1326.2009.01060.x.

PMID:
19515182
5.

Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.

Esposito K, Ciotola M, Maiorino MI, Gualdiero R, Schisano B, Ceriello A, Beneduce F, Feola G, Giugliano D.

Ann Intern Med. 2008 Oct 21;149(8):531-9.

PMID:
18936501
6.

Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.

Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N.

Clin Ther. 2007 Nov;29(11):2374-84.

PMID:
18158078
7.

Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study).

Garber AJ, Wahlen J, Wahl T, Bressler P, Braceras R, Allen E, Jain R.

Diabetes Obes Metab. 2006 Jan;8(1):58-66.

PMID:
16367883
9.

A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naive patients with Type 2 diabetes.

Fogelfeld L, Dharmalingam M, Robling K, Jones C, Swanson D, Jacober S.

Diabet Med. 2010 Feb;27(2):181-8. doi: 10.1111/j.1464-5491.2009.02899.x.

PMID:
20546262
11.

Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials.

Fonseca V, Davidson J, Home P, Snyder J, Jellinger P, Dyhr Toft A, Barnett A.

Curr Med Res Opin. 2010 Jul;26(7):1621-8. doi: 10.1185/03007995.2010.485087.

PMID:
20429817
12.

Comparison of insulin lispro protamine suspension and insulin detemir in basal-bolus therapy in patients with Type 1 diabetes.

Chacra AR, Kipnes M, Ilag LL, Sarwat S, Giaconia J, Chan J; COMPLETE T1D investigators.

Diabet Med. 2010 May;27(5):563-9. doi: 10.1111/j.1464-5491.2010.02986.x.

PMID:
20536953
13.

Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy.

Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH; Lispro Mixture-Glargine Study Group.

Clin Ther. 2004 Dec;26(12):2034-44. Erratum in: Clin Ther. 2005 Jul;27(7):1112.

PMID:
15823767
14.

PREDICTIVE- a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort.

Lüddeke HJ, Sreenan S, Aczel S, Maxeiner S, Yenigun M, Kozlovski P, Gydesen H, Dornhorst A; PREDICTIVE Study Group.

Diabetes Obes Metab. 2007 May;9(3):428-34.

PMID:
17391171
15.
16.

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

Clin Ther. 2008 Aug;30(8):1448-60. doi: 10.1016/j.clinthera.2008.08.006. Erratum in: Clin Ther. 2008 Oct;30(10):1937.

PMID:
18803987
17.
18.

Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial.

Davies M, Lavalle-González F, Storms F, Gomis R; AT.LANTUS Study Group.

Diabetes Obes Metab. 2008 May;10(5):387-99. doi: 10.1111/j.1463-1326.2008.00873.x. Epub 2008 Mar 18.

PMID:
18355327
19.

Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.

Derosa G, D'Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Cicero AF.

J Clin Pharm Ther. 2009 Feb;34(1):13-23. doi: 10.1111/j.1365-2710.2008.00984.x.

PMID:
19125899
20.
Items per page

Supplemental Content

Write to the Help Desk